Treatment of allergic conditions using a composition containing synthetic adjuvant
AssigneeInfectious Disease Research Institute
InventorsSteven G. Reed, Darrick Carter
Life of this patent
Estimating the term…
Abstract
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
Claims20
A method of treating an allergic condition in a subject comprising administering to the subject a composition comprising:
- a glucopyranosyl lipid adjuvant (GLA), of the formula
- where:
- R1, R3, R5 and R6 are undecyl;
- and
- R2 and R4 are tridecyl;
- wherein said composition is substantially devoid of an antigen;
- and
- wherein said composition stimulates an immune response in the subject thereby treating the allergic condition in the subject.
A method of treating an allergic condition comprising administering to the individual an effective amount of a composition comprising GLA of the formula
- where:
- R1, R3, R5 and R6 are undecyl;
- and
- R2 and R4 are tridecyl.
Dependencies are inferred from the claim text.